Dr. Quick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
543 Taylor Ave
Columbus, OH 43203Phone+1 614-293-4969Fax+1 614-293-6111
Education & Training
University of Vermont Medical CenterFellowship, Neuromuscular Medicine (Neurology), 2006 - 2007- University of Vermont Medical CenterResidency, Neurology, 2003 - 2006
- University of Vermont Medical CenterInternship, Internal Medicine, 2002 - 2003
Indiana University School of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2007 - 2026
VT State Medical License 2002 - 2007- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 3 citationsSafety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial.A Gordon Smith, J Robinson Singleton, Adrienne Aperghis, Christopher S Coffey, Peter Creigh
JAMA Neurology. 2023-12-01 - 39 citationsEffect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the...Sabrina Paganoni, Suzanne Hendrix, Samuel P Dickson, Newman Knowlton, James D Berry
Journal of Neurology, Neurosurgery, and Psychiatry. 2022-05-16 - 10 citationsSafety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.Merit Cudkowicz, Angela Genge, Nicholas J. Maragakis, Susanne Petri, Leonard H. van den Berg
The Lancet. Neurology. 2021-10-01
Press Mentions
New $158K/year ALS Drug Raises Hope for MoreOctober 17th, 2022
Radicava Hopes, Expectations from NFL’s William White and Doctors at Ohio StateAugust 16th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
